Drug Manufacturing

NeuroNOS secures funding for autism treatment development

As a part of a broader investment round, Beyond Air’s subsidiary NeuroNOS has received an initial equity financing of $2m from private investors, aimed at expediting the preclinical development of its small-molecule drug for paediatrics with autism.

Duke-NUS and NUS Medicine launch centre for metabolomics research

A collaborative effort between Duke-NUS Medical School and the National University of Singapore Yong Loo Lin School of Medicine (NUS Medicine) has led to the launch of the joint research centre named Systems Metabolomics Centre (SysMeC), aimed at metabolomics research.

FDA approves Novartis’ Fabhalta for C3 glomerulopathy treatment

The US Food and Drug Administration (FDA) has granted approval for Novartis’ Fabhalta (iptacopan), intended to minimise proteinuria in the adult population with C3 glomerulopathy (C3G).

Porton Advanced and Eureka to expedite T-cell therapy development

Contract development and manufacturing organisation (CDMO) Porton Advanced has announced a partnership with Eureka Therapeutics to expedite the worldwide clinical development of T-cell therapies.

Delpharm plans $140m investment to upgrade Boucherville facility in Canada

Contract development and manufacturing organisation (CDMO) Delpharm has announced plans to invest over C$200m ($140m) to modernise its Boucherville facility in Canada.

FDA grants orphan drug status for Korro Bio’s AATD therapy

The US Food and Drug Administration (FDA) has granted orphan drug designation for Korro Bio’s KRRO-110 to treat alpha-1 antitrypsin deficiency (AATD).

FDA clears PDS Biotechnology’s Versamune MUC1 combo for mCRC

The US Food and Drug Administration (FDA) has granted clearance for PDS Biotechnology's investigational new drug (IND) application to assess Versamune MUC1 plus PDS01ADC for the treatment of unresectable, metastatic colorectal carcinoma (mCRC).

LGM Pharma to expand manufacturing capabilities with $6m investment

LGM Pharma has announced more than $6m investment to expand its manufacturing facility in Rosenberg in the US state of Texas.

Aprea and MD Anderson sign agreement for APR-1051

Aprea Therapeutics has signed a material transfer agreement (MTA) with MD Anderson Cancer Center to explore APR-1051 for head and neck squamous cell carcinoma (HNSCC).